Ex Vivo News and Research

RSS

Human stem cells restore alveolar epithelial tissue after E. coli endotoxin-induced ALI: Researchers

Human stem cells administered intravenously can restore alveolar epithelial tissue to a normal function in a novel ex vivo perfused human lung after E. coli endotoxin-induced acute lung injury, according to research from the University of California San Francisco.

18 May 2010

FDA grants NeoPharm's IL13-PE38QQR orphan-drug designation for treatment of IPF

NeoPharm, Inc., announced today that the Office of Orphan Products Development of the United States Food and Drug Administration (FDA) has granted orphan-drug designation for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

17 May 2010

BioMarker Strategies receives $1M NCI grant funding to develop SnapPath live tumor cell testing system

BioMarker Strategies announced today that the National Cancer Institute (NCI) has approved the first $1 million in Phase II funding for the company's Small Business Innovative Research (SBIR) contract to develop the SnapPath™ live tumor cell testing system. The company is developing the SnapPath™ system to better enable drug companies to stratify patients in clinical trials, as well as assist oncologists in determining the most effective targeted drug treatment for their cancer patients.

4 May 2010

Study results from US Military Malaria Vaccine Program announced

Bioject Medical Technologies Inc., a leading developer of needle-free injection therapy systems, today announced that the US Military Malaria Vaccine Program presented results of its study using the Biojector2000 with a recombinant DNA vaccine at two recent conferences. A Cooperative Research and Development Agreement was signed with the Navy in April 2009 to work together on the study.

28 Apr 2010

NeoPharm seeks Orphan Drug Designation for IL13-PE38QQR in treatment of IPF

NeoPharm, Inc., announced today that it has filed an orphan drug application with the Office of Orphan Products Development of the United States Food and Drug Administration to have Orphan Drug Designation granted to IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis.

10 Mar 2010

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2009.

10 Mar 2010

BCRI study evaluates the effect of high-doses of vitamin C on inhibition of new blood vessel growth

Bio-Communications Research Institute's recent research study has found that high levels of vitamin C (ascorbate) inhibit the formation of new blood vessel growth to tumors.

27 Feb 2010

Clive Svendsen to receive American Academy of Neurology Sheila Essey Award for his research on ALS

Clive Svendsen, Ph.D., director of the Cedars-Sinai Regenerative Medicine Institute, is receiving the American Academy of Neurology Sheila Essey Award for his research on ALS (amyothrophic lateral sclerosis).

16 Feb 2010

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

ExThera Medical announced today that the results of a preliminary study (“Cytokines in blood from septic patients interact with surface immobilized heparin”) of its proprietary medical device, Seraph™ extracorporeal affinity therapy, have been published in the current issue of the Journal of the American Society for Artificial Organs (Jan.-Feb. 2010).

9 Feb 2010

HUCB-derived purified and expanded CD133+ cells may show promise in cellular cardiomyoplasty

Researchers at the Pontif-cia Universidade Cat-lica do Paran- and Instituto Carlos Chagas have evaluated the therapeutic potential of purified and expanded CD133+ cells human umbilical cord blood (HUCB)-derived in treating myocardial infarction by intramyocardially injecting them into a rat model. Patients who have high cardiovascular risks have fewer endothelial progenitor cells (EPCs) and their EPCs exhibit greater in vitro senescence.

4 Feb 2010

Pandemic H1N1 influenza of swine origin has distinct means of transmission from seasonal flu

Current research suggests that pandemic H1N1 influenza of swine origin has distinct means of transmission from the seasonal flu, yet does not result in the pathogenic severity of avian flu viruses.

2 Feb 2010

Copper-free version of click chemistry crafted to create biomolecular probes

For the first time, the widely used molecular synthesis technique known as click chemistry has been safely applied to a living organism. Researchers with Lawrence Berkeley National Laboratory (Berkeley Lab) and the University of California (UC) Berkeley have crafted a unique copper-free version of click chemistry to create biomolecular probes for in vivo studies of live mice. Conventional click chemistry reactions require a copper catalyst that is toxic to cells and organisms.

20 Jan 2010

NeoPharm submits IL13-PE38QQR IND for the treatment of IPF

NeoPharm, Inc., announced today that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for IL13-PE38QQR (IL13-PE) for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is the most deadly disease of the lungs in humans with very high morbidity. There is currently no proven effective treatment for the cure of this disease.

5 Jan 2010

Synta Pharmaceuticals announces study results of elesclomol

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced the results of a study evaluating the activity of elesclomol against acute myeloid leukemia (AML) cell lines and primary leukemic blast cells from AML patients, presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans.

7 Dec 2009

S*BIO to present data on its novel oral JAK2 inhibitor at The American Society of Hematology meeting

S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans.

2 Dec 2009

Indefinite expansion of adult cells without recourse to stem cell intermediates possible

Is the indefinite expansion of adult cells possible without recourse to stem cell intermediates? The team led by Michael Sieweke at the Centre d'immunologie de Marseille Luminy (Université Aix-Marseille 2 / CNRS / INSERM) has proved that this is the case by achieving the ex vivo regeneration for several months of macrophages, specialized cells in the immune system.

16 Nov 2009

Gamida Cell and Cellerixon collaborate to develop new line of cell therapeutics

Gamida Cell Ltd. and Cellerix, S.A. announced today that the companies are collaborating on a feasibility study to evaluate the added value of combining the proprietary technologies of each.

21 Oct 2009

Article evaluating StemEx therapy for leukemia and lymphoma to be published

Gamida Cell announced today the publication of an article evaluating carlecortemcel-l, the generic name of what is widely known as "StemEx", as a therapy for blood cancers such as leukemia and lymphoma.

19 Oct 2009

BioTech Medics' SHBAN Hand Sanitizer Solution kills H1N1 Influenza A virus

BioTech Medics, Inc. announces that it has received independent clinical testing results of its SHBAN™ Hand Sanitizer Solution to prove SHBAN™ kills the H1N1 (Swine) Influenza A virus.

15 Oct 2009

Covidien launches V-Loc absorbable wound closure device

Covidien, a leading global provider of healthcare products, today announced the global rollout of the V-Loc™ absorbable wound closure device, the first surgical device of its kind to feature unidirectional barbed technology that enables surgeons to close dermal wounds quickly and securely without tying knots.

13 Oct 2009